Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
-6.4%  /
91.4%
25.6x
11.8x
1.9x
7.4%
9.7%
..
1.7%
5.4% 
-55.9%  /
57.5%
>200x
86.1x
35.1x
17.3%
335.0%
2025-11-06
0.0%
9.2% 
10.0%  /
30.3%
21.5x
10.9x
4.7x
22.3%
21.5%
..
0.1%
4.5% 
-43.9%  /
25.9%
1.8x
2.1x
0.5x
27.2%
-0.9%
2025-11-05
1.4%
-2.7% 
7.3%  /
7.3%
3.2x
3.5x
0.8x
26.4%
-10.6%
..
1.9%
-38.3% 
3.8%  /
4.3%
23.7x
15.7x
1.4x
5.9%
0.0%
..
0.5%
--- 
0.0%  /
0.0%
>200x
>200x
52.1x
0.0%
0.0%
..
0.0%
-87 747 375.1% 
0.0%  /
-16.7%
>200x
>200x
303.9x
0.0%
0.0%
..
0.0%
-6.9% 
-48.4%  /
-18.6%
7.2x
5.5x
2.2x
30.0%
105.9%
2026-02-05
0.9%
51.0% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2025-11-07
#reports #YELP

[Yelp](https://eninvs.com/all.php?name=YELP) (Crowdsourcing platform) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue +4.4% YoY (vs +3.6% in previous quarter and historical rate +8.3%)
- EBITDA +18.2% YoY (vs +34.7% in previous quarter and historical rate +56.1%)
- EBITDA margin 20.7% increased compared to 18.3% same period last year
- Net Debt decreased by $35 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0 bln (negative), 0.4% of market cap
- EV/EBITDA multiple is 6.5x compared to historical level (75th percentile) of 20.8x
- EV/Sales multiple is 1.2x

2025-11-07
#reports #XRAY

[DENTSPLY SIRONA](https://eninvs.com/all.php?name=XRAY) (Dental materials and equipment manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193370)
(2025-11-06, Before Market Open):

- Revenue -4.9% YoY (vs -4.9% in previous quarter and historical rate +4.6%)
- EBITDA margin -16.4% increased compared to -45.1% same period last year
- Net Debt decreased by $26 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 5.7% of market cap
- EV/Sales multiple is 0.8x

At the opening of the session the share price went down -10.0% vs S&P500 -0.4%
2025-11-07
#reports #XPOF

[Xponential Fitness, Inc.](https://eninvs.com/all.php?name=XPOF) (Leisure) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue -1.2% YoY (vs -1.3% in previous quarter and historical rate +13.8%)
- EBITDA margin 8.9% increased compared to -2.5% same period last year
- Net Debt decreased by $75 mln over the past reporting period (34.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 36.3% of market cap
- EV/Sales multiple is 2.9x

2025-11-07
#reports #WSC

[WillScot](https://eninvs.com/all.php?name=WSC) (Warehouse service provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193366)
(2025-11-06, After Market Close):

- Revenue -5.7% YoY (vs -2.6% in previous quarter and historical rate +1.8%)
- EBITDA +392.7% YoY (vs +207.1% in previous quarter and historical rate +22.6%)
- EBITDA margin 35.6% increased compared to 6.8% same period last year
- Net Debt decreased by $52 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) -$0 bln (negative), 0.5% of market cap
- EV/EBITDA multiple is 8.7x compared to historical level (75th percentile) of 15.1x
- EV/Sales multiple is 3.2x

2025-11-07
#reports #WRBY

[Warby Parker Inc.](https://eninvs.com/all.php?name=WRBY) (Medical Instruments and Supplies) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193365)
(2025-11-06, Before Market Open):

- Revenue +15.6% YoY (vs +13.8% in previous quarter and historical rate +13.3%)
- EBITDA +333.3% YoY (vs -600.0% in previous quarter and historical rate +83.3%)
- EBITDA margin 5.9% increased compared to 1.6% same period last year
- Net Debt increased by $10 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0 bln (negative), 0.3% of market cap
- EV/EBITDA multiple is 67.6x compared to historical level (75th percentile) of 306x
- EV/Sales multiple is 2.4x

At the opening of the session the share price went up +2.1% vs S&P500 -0.4%
2025-11-07
#reports #VTRS

[Viatris](https://eninvs.com/all.php?name=VTRS) (Medicines manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193362)
(2025-11-06, Before Market Open):

- Revenue +0.2% YoY (vs -5.7% in previous quarter and historical rate -5.4%)
- EBITDA -20.9% YoY (vs +73.4% in previous quarter and historical rate -22.0%)
- EBITDA margin 11.5% decreased compared to 14.6% same period last year
- Net Debt decreased by $442 mln over the past reporting period (3.6% of market cap)
- FCF (LTM) -$0.5 bln (negative), 3.9% of market cap
- EV/EBITDA multiple is 145.4x compared to historical level (75th percentile) of 11.6x
- EV/Sales multiple is 1.8x

2025-11-07
#reports #VHI

[Valhi](https://eninvs.com/all.php?name=VHI) (Chemicals) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193361)
(2025-11-06, After Market Close):

- Revenue +8% YoY (vs -1.4% in previous quarter and historical rate -3.6%)
- EBITDA -60.7% YoY (vs -55.0% in previous quarter and historical rate +37.0%)
- EBITDA margin 4.6% decreased compared to 12.6% same period last year
- Net Debt increased by $28 mln over the past reporting period (7.4% of market cap)
- FCF (LTM) -$0.2 bln (negative), 43.1% of market cap
- EV/EBITDA multiple is 4x compared to historical level (75th percentile) of 12x
- EV/Sales multiple is 0.6x

2025-11-07
#reports #VERI

[Veritone](https://eninvs.com/all.php?name=VERI) (Software — Infrastructure) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue +31.8% YoY (vs -22.6% in previous quarter and historical rate -12.9%)
- EBITDA margin -27.6% increased compared to -68.2% same period last year
- Net Debt decreased by $23 mln over the past reporting period (7.3% of market cap)
- FCF (LTM) +$0 bln (positive), 8.5% of market cap
- EV/Sales multiple is 4.1x

2025-11-07
#reports #VCEL

[Vericel](https://eninvs.com/all.php?name=VCEL) (Medical services provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193360)
(2025-11-06, Before Market Open):

- Revenue +17.2% YoY (vs +18.9% in previous quarter and historical rate +17.5%)
- EBITDA margin 8.8% increased compared to -1.7% same period last year
- Net Debt decreased by $20 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.7% of market cap
- EV/EBITDA multiple is 132.6x compared to historical level (75th percentile) of 747.3x
- EV/Sales multiple is 7.2x

At the opening of the session the share price went up +11.9% vs S&P500 -0.4%
2025-11-07
#reports #URGN

[UroGen Pharma](https://eninvs.com/all.php?name=URGN) (Biotechnology) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193358)
(2025-11-06, Before Market Open):

- Revenue +8% YoY (vs +9.1% in previous quarter and historical rate +15.3%)
- EBITDA margin -100.0% decreased compared to -68.0% same period last year
- Net Debt increased by $32 mln over the past reporting period (2.8% of market cap)
- FCF (LTM) -$0.1 bln (negative), 8.6% of market cap
- EV/Sales multiple is 11.7x

At the opening of the session the share price went down -5.3% vs S&P500 -0.4%
2025-11-07
#reports #UPLD

[Upland Software](https://eninvs.com/all.php?name=UPLD) (Software — Application) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193357)
(2025-11-06, Before Market Open):

- Revenue -23.9% YoY (vs -23.2% in previous quarter and historical rate -9.1%)
- EBITDA +7.1% YoY (vs -72.7% in previous quarter)
- EBITDA margin 29.4% increased compared to 20.9% same period last year
- Net Debt decreased by $35 mln over the past reporting period (66.7% of market cap)
- FCF (LTM) +$0.2 bln (positive), 314.4% of market cap
- EV/EBITDA multiple is 18.3x compared to historical level (75th percentile) of 68.9x
- EV/Sales multiple is 3.4x

At the opening of the session the share price went up +1.6% vs S&P500 -0.4%
2025-11-07
#reports #UEIC

[Universal Electronics](https://eninvs.com/all.php?name=UEIC) ( Innovative products manufacturer) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue -10.8% YoY (vs +8.9% in previous quarter and historical rate -10.8%)
- EBITDA -120% YoY (vs 0.0% in previous quarter)
- EBITDA margin -1.1% decreased compared to 4.9% same period last year
- Net Debt decreased by $10 mln over the past reporting period (22.8% of market cap)
- FCF (LTM) +$0 bln (positive), 43.4% of market cap
- EV/Sales multiple is 0.1x

2025-11-07
#reports #TXG

[10X Genomics](https://eninvs.com/all.php?name=TXG) (Medical services provider) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue -2% YoY (vs +13.1% in previous quarter and historical rate +9.0%)
- EBITDA margin -17.4% increased compared to -23.0% same period last year
- Net Debt decreased by $34 mln over the past reporting period (2.3% of market cap)
- FCF (LTM) +$0 bln (positive), 3.3% of market cap
- EV/Sales multiple is 1.7x

2025-11-07
#reports #TTEC

[TTEC](https://eninvs.com/all.php?name=TTEC) (IT services provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193354)
(2025-11-06, After Market Close):

- Revenue -1.9% YoY (vs -3.7% in previous quarter and historical rate -3.6%)
- EBITDA -7.9% YoY (vs +4100.0% in previous quarter and historical rate -12.9%)
- EBITDA margin 6.7% decreased compared to 7.2% same period last year
- Net Debt decreased by $2 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 87.2% of market cap
- EV/EBITDA multiple is 6.6x compared to historical level (75th percentile) of 9.2x
- EV/Sales multiple is 0.5x

2025-11-07
#reports #TRIP

[TripAdvisor](https://eninvs.com/all.php?name=TRIP) (Travel services provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193351)
(2025-11-06, Before Market Open):

- Revenue +3.9% YoY (vs +6.4% in previous quarter and historical rate +13.1%)
- EBITDA +3.3% YoY (vs +46.4% in previous quarter and historical rate +10.0%)
- EBITDA margin 17.0% decreased compared to 17.1% same period last year
- Net Debt decreased by $11 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.3 bln (negative), 13.7% of market cap
- EV/EBITDA multiple is 10.7x compared to historical level (75th percentile) of 14.5x
- EV/Sales multiple is 1.2x

At the opening of the session the share price went up +6.4% vs S&P500 -0.4%
2025-11-07
#reports #TPR

[Tapestry](https://eninvs.com/all.php?name=TPR) (Clothes seller) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193349)
(2025-11-06, Before Market Open):

- Revenue +13.1% YoY (vs -74.2% in previous quarter and historical rate +6.6%)
- EBITDA +25.9% YoY (vs -62.3% in previous quarter and historical rate +8.4%)
- EBITDA margin 21.6% increased compared to 19.4% same period last year
- Net Debt increased by $676 mln over the past reporting period (2.8% of market cap)
- FCF (LTM) +$0.3 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 19.5x compared to historical level (75th percentile) of 8.6x
- EV/Sales multiple is 4.8x

At the opening of the session the share price went down -13.5% vs S&P500 -0.4%
2025-11-07
#reports #TNDM

[Tandem Diabetes Care](https://eninvs.com/all.php?name=TNDM) (Medical equipment manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193348)
(2025-11-06, After Market Close):

- Revenue +2% YoY (vs +8.6% in previous quarter and historical rate +9.4%)
- EBITDA margin -8.0% increased compared to -9.4% same period last year
- Net Debt decreased by $4 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.1 bln (negative), 15.3% of market cap
- EV/Sales multiple is 1x

2025-11-07
#reports #TMCI

[Treace Medical Concepts, Inc.](https://eninvs.com/all.php?name=TMCI) (Medical Devices) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193347)
(2025-11-06, After Market Close):

- Revenue +11.1% YoY (vs +6.8% in previous quarter and historical rate +21.1%)
- EBITDA margin -26.0% increased compared to -28.9% same period last year
- Net Debt increased by $11 mln over the past reporting period (3.2% of market cap)
- FCF (LTM) -$0 bln (negative), 3.2% of market cap
- EV/Sales multiple is 1.6x

2025-11-07
#reports #TKNO

[Alpha Teknova, Inc.](https://eninvs.com/all.php?name=TKNO) (Drug Manufacturers — Specialty and Generic) reported for 2025 q3
(2025-11-06, After Market Close):

- Revenue 0% YoY (vs 0.0% in previous quarter and historical rate -2.8%)
- EBITDA margin -40.0% increased compared to -70.0% same period last year
- Net Debt increased by $2 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) -$0 bln (negative), 2.2% of market cap
- EV/Sales multiple is 3.6x

2025-11-07
#reports #THR

[Thermon Group](https://eninvs.com/all.php?name=THR) (Specialty Industrial Machinery) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193346)
(2025-11-06, Before Market Open):

- Revenue 0% YoY (vs -5.2% in previous quarter and historical rate +7.6%)
- EBITDA 0% YoY (vs -10.5% in previous quarter and historical rate +10.4%)
- EBITDA margin 18.3% has not changed compared to 18.3% same period last year
- Net Debt increased by $7 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0 bln (positive), 2.7% of market cap
- EV/EBITDA multiple is 13.1x compared to historical level (75th percentile) of 13.3x
- EV/Sales multiple is 2.5x

At the opening of the session the share price went up +8.8% vs S&P500 -0.4%
2025-11-07
#reports #TH

[Target Hospitality](https://eninvs.com/all.php?name=TH) (Oil and Gas Equipment and Services) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=193345)
(2025-11-06, Before Market Open):

- Revenue +4.2% YoY (vs -38.6% in previous quarter and historical rate -1.6%)
- EBITDA -53.1% YoY (vs -106.7% in previous quarter and historical rate -5.4%)
- EBITDA margin 15.2% decreased compared to 33.7% same period last year
- Net Debt decreased by $36 mln over the past reporting period (5.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 26.8% of market cap
- EV/EBITDA multiple is 12.6x compared to historical level (75th percentile) of 6.9x
- EV/Sales multiple is 2x

At the opening of the session the share price went up +3.6% vs S&P500 -0.4%